Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,588 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Paclitaxel Clear all
Completed Phase 3 Interventional Results available

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

NCT01196390
View directory record Official record
Conditions
Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Cancer AJCC v7, Stage IIA Esophageal Cancer AJCC v7, Stage IIB Esophageal Cancer AJCC v7, Stage IIIA Esophageal Cancer AJCC v7, Stage IIIB Esophageal Cancer AJCC v7
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Radiation Therapy, Therapeutic Conventional Surgery, Trastuzumab
Drug · Other · Radiation + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
634
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 407 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 2, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment

NCT04083235
View directory record Official record
Conditions
Metastatic Adenocarcinoma of the Pancreas
Interventions
Irinotecan Liposomal Injection, Oxaliplatin, 5Fluorouracil, Leucovorin, Nab-paclitaxel, Gemcitabine
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
72
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 2, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer

NCT00986674
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
cixutumumab, carboplatin, paclitaxel, cetuximab
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
249
States / cities
Stanford, California • Aurora, Colorado • Boulder, Colorado + 171 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Sep 2, 2026, 5:22 AM EDT
Completed Not applicable Interventional Results available

Hand Therapy Intervention Versus Traditional Occupational Therapy to Prevent Chemotherapy Induced Peripheral Neuropathy

NCT05374876
View directory record Official record
Conditions
Adenocarcinoma of Pancreas
Interventions
Hand Therapy Until CIPN, Traditional Occupational Therapy (TOT)
Other
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 2, 2026, 5:22 AM EDT
Recruiting Phase 1 Interventional

Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer

NCT06639724
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)
Combination Product
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 2, 2026, 5:22 AM EDT
Completed Phase 1 Interventional Results available

Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors

NCT01831089
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Gynecological Cancer, Head and Neck Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Non-squamous Cell Lung Cancer
Interventions
PM01183 + paclitaxel +/- bevacizumab
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Sep 2, 2026, 5:22 AM EDT
Not listed Phase 1 Interventional

A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer

NCT03435289
View directory record Official record
Conditions
Pancreatic Cancer, Metastatic Pancreatic Cancer
Interventions
CPI 613 in Combination With Gemcitabine and Nab-paclitaxel
Drug
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Morristown, New Jersey • Summit, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 18, 2018 · Synced Sep 2, 2026, 5:22 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer

NCT00140140
View directory record Official record
Conditions
Stage IV (Metastatic) Breast Cancer
Interventions
ABI-007, vinorelbine, Trastuzumab, G-CSF
Drug · Biological
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Duarte, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Sep 2, 2026, 5:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment

NCT00421889
View directory record Official record
Conditions
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Bladder Cancer
Interventions
belinostat, Paclitaxel, Carboplatin
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
7
States / cities
Newport Beach, California • Orlando, Florida • Covington, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2015 · Synced Sep 2, 2026, 5:22 AM EDT
Completed Phase 1 Interventional

A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer

NCT02429843
View directory record Official record
Conditions
Lung Cancer
Interventions
TRC105
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 27, 2021 · Synced Sep 2, 2026, 5:22 AM EDT
Completed Phase 3 Interventional

Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer

NCT00002717
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
cisplatin, paclitaxel
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
52
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 26, 2013 · Synced Sep 2, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)

NCT03976362
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Non-small-cell Lung
Interventions
Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel, Olaparib, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
851 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
18
States / cities
Birmingham, Alabama • Burbank, California • Boca Raton, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 2, 2026, 5:22 AM EDT
Recruiting Not applicable Interventional

Virtue® SAB in the Treatment of Coronary ISR Trial

NCT07045194
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Virtue Sirolimus AngioInfusion Balloon, AGENT™ Paclitaxel Drug-Coated Balloon
Device
Lead sponsor
Orchestra BioMed, Inc
Industry
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
15
States / cities
Gainesville, Florida • Pensacola, Florida • Indianapolis, Indiana + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 2, 2026, 5:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery

NCT02730546
View directory record Official record
Conditions
Gastric Cardia Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Gastric Cancer AJCC v7, Stage II Gastric Cancer AJCC v7, Stage IIA Gastric Cancer AJCC v7, Stage IIB Gastric Cancer AJCC v7, Stage IIIA Gastric Cancer AJCC v7, Stage IIIB Gastric Cancer AJCC v7
Interventions
Carboplatin, Computed Tomography, Fluorouracil, Laboratory Biomarker Analysis, Leucovorin Calcium, Oxaliplatin, Paclitaxel, Pembrolizumab, Positron Emission Tomography, Radiation Therapy, Therapeutic Conventional Surgery
Drug · Procedure · Other + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Phoenix, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Sep 2, 2026, 5:22 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer

NCT02399137
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
MM-141, Placebo, Gemcitabine, Nab-Paclitaxel
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
47
States / cities
Gilbert, Arizona • Anaheim, California • Fullerton, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Sep 2, 2026, 5:22 AM EDT
Completed Phase 1 Interventional Results available

Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian

NCT01219777
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions
carboplatin, Bevacizumab, Paclitaxel
Drug
Lead sponsor
Ritu Salani
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Sep 2, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer

NCT00403130
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer
Interventions
Gemcitabine, Paclitaxel, Bevacizumab
Drug
Lead sponsor
George Albert Fisher
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Sep 2, 2026, 5:22 AM EDT
Terminated Phase 3 Interventional Results available

Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology

NCT00596830
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Carcinoma, Adenosquamous, Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung
Interventions
CP-751,871 (Figitumumab), Carboplatin, Paclitaxel
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
169
States / cities
Florence, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 133 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2014 · Synced Sep 2, 2026, 5:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies

NCT01325441
View directory record Official record
Conditions
Cancer
Interventions
BBI608, Paclitaxel
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
17
States / cities
Los Angeles, California • Denver, Colorado • Indianapolis, Indiana + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Sep 2, 2026, 5:22 AM EDT
Terminated Phase 1 Interventional

Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel

NCT02138812
View directory record Official record
Conditions
Medical Oncology
Interventions
BAY1161909, Paclitaxel
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Santa Monica, California • New Haven, Connecticut • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 2, 2026, 5:22 AM EDT
Terminated Not applicable Interventional Results available

Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer

NCT01367301
View directory record Official record
Conditions
Stage IA Uterine Sarcoma, Stage IB Uterine Sarcoma, Stage IC Uterine Sarcoma, Stage IIA Uterine Sarcoma, Stage IIB Uterine Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma, Stage IIIC Uterine Sarcoma, Stage IVA Uterine Sarcoma, Stage IVB Uterine Sarcoma, Uterine Carcinosarcoma
Interventions
paclitaxel, carboplatin, external beam radiation therapy, brachytherapy, intensity-modulated radiation therapy, laboratory biomarker analysis
Drug · Radiation · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Sep 2, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma

NCT00111007
View directory record Official record
Conditions
Melanoma
Interventions
Sorafenib (Nexavar, BAY43-9006), Carboplatin/Paclitaxel, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Sep 2, 2026, 5:22 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver

NCT04175912
View directory record Official record
Conditions
Metastatic Cholangiocarcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Cholangiocarcinoma, Unresectable Hepatocellular Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Carboplatin, Paclitaxel, Pevonedistat
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
419
States / cities
Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 254 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 2, 2026, 5:22 AM EDT
Completed Phase 1 Interventional

Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

NCT00079430
View directory record Official record
Conditions
Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Primary Peritoneal Cavity Cancer, Stage II Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Interventions
adjuvant therapy, paclitaxel, carboplatin, bevacizumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
17
States / cities
Orange, California • Chicago, Illinois • Iowa City, Iowa + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2019 · Synced Sep 2, 2026, 5:22 AM EDT